Last updated on July 2020

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Brief description of study

For Groups 1 to 4, the primary objective of this study is to estimate the clinical benefit of cemiplimab monotherapy for patients with: metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC. For Group 6, the primary objective is to provide additional efficacy and safety data for cemiplimab monotherapy in patients with advanced CSCC (metastatic [nodal or distant] or locally advanced. Clinical benefit is measured by overall response rate (ORR) according to central review in each group.

Clinical Study Identifier: NCT02760498

Find a site near you

Start Over

Mayo Clinic

Phoenix, AZ United States
  Connect »

City of Hope Hospital

Duarte, CA United States
  Connect »

Stanford University

Redwood City, CA United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »

St. Louis University

Saint Louis, MO United States
  Connect »

New York University

New York, NY United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Huntsman Cancer Institute

Salt Lake City, UT United States
  Connect »

Adelaide Cancer Centre

Kurralta Park, Australia
  Connect »

CHRU Grenoble

Grenoble, France
  Connect »

Gosford Hospital

Gosford, Australia
  Connect »

Liverpool Hospital

Liverpool, Australia
  Connect »


Lages, Brazil
  Connect »

Waikato Hospital

Hamilton, New Zealand
  Connect »

Rotorua Hospital

Rotorua, New Zealand
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.